<DOC>
	<DOCNO>NCT01674634</DOCNO>
	<brief_summary>The primary objective study assess safety two concurrent injection AA4500 hand subject multiple Dupuytren 's contracture palpable cord follow 24 72 hour later finger extension procedure compare rate occurrence target serious adverse event ( tendon rupture/ligament injury anaphylaxis ) historical rate clinical study post-marketing commercial use . The secondary objective evaluate efficacy two concurrent injection AA4500 .</brief_summary>
	<brief_title>Safety Efficacy Two Concurrent Injections AA4500 Adult Subjects With Multiple Dupuytren 's Contractures</brief_title>
	<detailed_description>Methodology/Study Design : After pre-injection procedure complete Day 1 , eligible men woman receive two concurrent injection AA4500 ( AA4500/AA4500 ) cord ( ) affect MP and/or PIP joint different finger select hand . A finger extension procedure facilitate cord disruption perform ( administration local anesthesia , need ) 24 72 hour injection subject spontaneous disruption cord ( ) . Follow visit evaluation safety efficacy require subject 24 72 hour injection , Days 15 , 31 , 61 . Upon completion day 61 follow-up visit ( end study visit ) , subject require additional treatment treat hand may receive three additional injection AA4500 accord XIAFLEX package insert . Subjects may receive total five injection individual cord may receive total three injection . Subjects require additional treatment follow safety .</detailed_description>
	<mesh_term>Contracture</mesh_term>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>1 . Provide sign date informed consent 2 . Be man woman ≥ 18 year age 3 . Have diagnosis Dupuytren 's disease least 2 fixedflexion contracture hand ≥ 20º PIP and/or MP joint finger , thumb , cause palpable cord ( ) suitable treatment 4 . Have positive `` table top test '' define inability simultaneously place affect finger ( ) palm flat table top 5 . Have negative urine pregnancy test screen injection study drug use highly effective ( ie , &lt; 1 % failure rate ) contraception method judge investigator ( eg , abstinence , intrauterine device [ IUD ] , hormonal [ estrogen/progestin ] contraceptive , barrier control ) least one menstrual cycle prior study enrollment duration study surgically sterile ( female childbearing potential ) ; postmenopausal female ( menses least 1 year hysterectomy ) . 6 . Be able comply study visit schedule specify protocol A subject exclude study participation he/she : 1 . Received surgery ( fasciectomy surgical fasciotomy ) and/or needle aponeurotomy/fasciotomy select joint treat within 6 month administration study drug 2 . Has chronic muscular , neurological , neuromuscular disorder affect hand 3 . Has know systemic allergy collagenase excipient AA4500 4 . Has receive collagenase treatment ( eg , Santyl® ointment and/or XIAFLEX®/XIAPEX® ) within 30 day injection study drug hand select treatment 5 . Is currently receive plan receive anticoagulant medication receive anticoagulant medication ( except ≤ 150 mg aspirin daily ) within 7 day injection study drug 6 . Has know recent history stroke , bleeding , medical condition , investigator 's opinion would make subject unsuitable enrollment study 7 . Received investigational drug within 30 day injection study drug 8 . Is pregnant intend become pregnant study breastfeed child 9 . Has clinically significant medical history condition ( ) , include condition affect hand , would , opinion investigator , substantially increase risk associate subject 's participation protocol compromise scientific objective study 10 . Has jewelry hand treat remove</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>XIAFLEX</keyword>
	<keyword>XIAPEX</keyword>
	<keyword>Dupuytren 's disease</keyword>
	<keyword>contracture</keyword>
</DOC>